Clinical trials: Allogeneic Disease
Graft vs Host Disease, Alogenic Hematopoietic Transplant
Rituximab for GVHD
This is a prospective, open-label pilot study in which 4 doses of Rituximab are administered to patients who have developed SR-aGVHD following allogeneic hematopoietic transplant (AHT).
- Trial name
- Rituximab GVHD (NCT00578591)
- Testing
- Rituximab
- Where
- 2 sites in United States
- Sponsor
- Baylor College of Medicine
Leukemia, Myeloid
High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML
The purpose of this study is to evaluate the safety and efficiency of high dose allogeneic mismatched hematopoietic stem cells infusions after normal chemotherapy in patients with relapsed/refractory acute myeloid leukemia（AML）.
- Trial name
- NCT03080922
- Testing
- hematopoietic stem cell
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Adenovirus Infections, Human
Incidence and Outcomes Associated With the Management of Adenovirus Infections in Allogenic Hematopoietic Cell Transplant Recipients
To depict the incidence, outcomes and standards of care (SoC) of adenovirus (AdV) infections and associated practice patterns in allogeneic hematopoietic cell transplant recipients.
- Trial name
- AdVance (NCT04285788)
- Volunteers
- 216 people
- Sponsor
- Jazz Pharmaceuticals
Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant
This phase I trial studies the side effects and the best dose of intensity modulated total marrow irradiation (IMTMI) when given together with fludarabine phosphate and melphalan in treating patients with cancers of the blood…
- Conditions
- Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hematologic Malignancy
- Trial name
- NCT02333162
- Testing
- Fludarabine Phosphate, Melphalan, Intensity-Modulated Radiation Therapy
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Acute Myeloid Leukemia (AML)
Allogeneic HCT Using Conditioning Regimen of BuFluATG for AML CR1
1. Study Objectives To evaluate the effect of various clinical variables including HLA-disparity and NK cell-related variables, upon outcomes of allogeneic hematopoietic cell transplantation (HCT) using uniform conditioning…
- Trial name
- NCT07155382
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Asan Medical Center
Leukemia, Myeloid, Acute
Post-transplant Flotetuzumab for AML
The purpose of this research study is to determine if the study drug, flotetuzumab, is safe and tolerable when given to participants with acute myeloid leukemia (AML) that has relapsed after transplant.
- Trial name
- NCT05506956
- Testing
- Flotetuzumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Leukemia, Lymphoma
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
RATIONALE: Aldesleukin may stimulate natural killer cells to kill cancer cells. Treating natural killer cells with aldesleukin in the laboratory may help the natural killer cells kill more cancer cells when they are put back in…
- Trial name
- NCT00625729
- Testing
- aldesleukin, allogeneic natural killer cells, rituximab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
T2D
BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients
The aim of this preliminary study is to evaluate the safety and efficacy of bone-marrow mononuclear cells (BM-MNCs) and umbilical-cord tissue-derived mesenchymal stem cells (UC-MSCs) administration in type 2 diabetes patients
- Trial name
- NCT04501341
- Testing
- Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC, Intravenous Infusion of UC-MSC
- Where
- Indonesia
- Volunteers
- 15 people
- Sponsor
- Universitas Indonesia
Allogeneic Haplo-Stem Cell Transplatation (SCT), Graft Versus Host Disease
A Study to Evaluate the Effect of ATG-F on Engraftment, Graft Versus Host Disease (GVHD) and Graft Versus Leukemia (GVL) Effect in Haplo-identical SCT
This study is planned to evaluated whether ATG is needed in haploidentical stem cell transplantation
- Trial name
- NCT00616954
- Testing
- ATG-F
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Hadassah Medical Organization
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain
This phase I/II trial tests the safety, side effects, and best dose of universal donor UD TGFbetai natural killer (NK) cells, and whether UD TGFbetai NK cells with temozolomide works to shrink tumors in patients with stage IV…
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT05588453
- Testing
- Natural Killer Cell Therapy, Temozolomide
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Kari Kendra
Infection
Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant
Patients enrolled on this study will have received a stem cell transplant. After a transplant, while the immune system grows back the patient is at risk for infection.
- Trial name
- CHARMS (NCT02108522)
- Testing
- Multivirus Specific T cells
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- AlloVir
Leukemia, Lymphoma
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00002502
- Testing
- busulfan, cyclophosphamide, cytarabine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR
This research study is for subjects that are receiving a bone marrow transplant. As part of the transplant subjects will receive stem cells from a donor who has agreed to donate stem cells for them.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- TAR (NCT01611298)
- Testing
- Tetanus
- Where
- 2 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Robert Krance
Leukemia, Lymphoblastic
ETOILE : A Feasibility Study in Pediatric Patient Education
Feasibility study of a therapeutic education program for the patient and his carers, intended for children suffering from acute lymphoblastic leukemia or having received an allograft of hematopoietic stem cells in the pediatric…
- Trial name
- ETOILE (NCT04399863)
- Testing
- ETOILE therapeutic education
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematologic Malignancies, Nonmalignant Diseases
Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)
Fludarabine and clofarabine are chemotherapy drugs used extensively in bone marrow transplantation. The goal of this study is to determine what causes some children to have different drug concentrations of clofarabine and…
- Conditions
- Hematologic Malignancies, Nonmalignant Diseases, Immunodeficiencies, Hemoglobinopathies
- Trial name
- NCT03609814
- Testing
- Clofarabine, Fludarabine Injection
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
Hurler Syndrome
Administration of IV Laronidase Post Bone Marrow Transplant in Hurler
This is a single center pilot study in which Laronidase will be given weekly for two years in patients with Hurler syndrome, also known as mucopolysaccharide IH (MPS I, Hurler syndrome), that have previously been treated with an…
- Trial name
- NCT01173016
- Testing
- Laronidase
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Diffuse Intrinsic Pontine Glioma, Medulloblastoma, Childhood, Recurrent
Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy
The aim of this study is to assess the safety and efficacy of AloCELYVIR, which consist in bone marrow-derived allogenic mesenchymal stem cells infected with an oncolytic Adenovirus, ICOVIR-5.
- Trial name
- AloCELYVIR (NCT04758533)
- Testing
- AloCELYVIR
- Where
- Spain
- Volunteers
- 13 people
- Sponsor
- Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
This phase II trial studies how well ibrutinib works in treating patients after a donor stem cell transplant for lymphoma that is not responding to treatment or has come back.
- Conditions
- Blastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Hodgkin Lymphoma
- Trial name
- NCT02869633
- Testing
- Ibrutinib, Laboratory Biomarker Analysis
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation
Pediatric GVHD Low Risk Steroid Taper Trial
The standard treatment for acute graft-vs-host disease (GVHD) is to suppress the activity of the donor immune cells using steroid medications such as prednisone.
- Conditions
- Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
- Trial name
- NCT05090384
- Testing
- Prednisone
- Where
- 11 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- John Levine
Myelodysplastic Syndromes, Acute Myeloid Leukemia
SGI-110 and Donor Lymphocyte Infusions (DLI) After Allogeneic Stem Cell Transplantation
High risk MDS (Myelodysplastic Syndrome) patients will be treated with SGI-110 after Allogeneic Stem Cell Transplantation in the hypothesis that SGI-110 maintenance given early after HSCT can prevent relapse without increasing…
- Trial name
- NCT03454984
- Testing
- Guadecitabine
- Where
- 12 sites in France
- Volunteers
- 40 people
- Sponsor
- Groupe Francophone des Myelodysplasies
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.